.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Army
Citi
Novartis
Daiichi Sankyo
Baxter
Cipla
Queensland Health
UBS
Mallinckrodt

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,451,991

« Back to Dashboard

Which drugs does patent 6,451,991 protect, and when does it expire?


Patent 6,451,991 protects KYNAMRO and is included in one NDA.

This patent has twenty-two patent family members in twenty countries.

Summary for Patent: 6,451,991

Title: Sugar-modified gapped oligonucleotides
Abstract:Oligonucleotides are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary nucleic acid strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleosides that activate RNase H. Such oligonucleotides are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to ooligonucleotide therapeutics.
Inventor(s): Martin; Pierre (Rheinfelden, CH), Altmann; Karl-Heinz (Reinach, CH), Cook; Phillip Dan (Vista, CA), Monia; Brett P. (Carlsbad, CA)
Assignee: ISIS Pharmaceuticals, Inc. (Carlsbad, CA) Novartis AG (CH)
Application Number:08/802,331
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Kastle Theraps Llc
KYNAMRO
mipomersen sodium
SOLUTION;SUBCUTANEOUS203568-001Jan 29, 2013RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,451,991

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway983718► Subscribe
Japan4293636► Subscribe
Japan2000504725► Subscribe
Israel125759► Subscribe
Hungary9901118► Subscribe
Spain2221039► Subscribe
European Patent Office0882061► Subscribe
Denmark0882061► Subscribe
Slovakia109198► Subscribe
New Zealand331217► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Julphar
Express Scripts
Dow
Federal Trade Commission
McKesson
Deloitte
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot